Metabolic characterisation of transglutaminase 2 inhibitor effects in breast cancer cell lines
The FEBS Journal · 2023
DOI: 10.1111/febs.16931 ↗Kurz gefasst
Fachartikel in der Zeitschrift The FEBS Journal, 2023. Verfasst von Mariana Gallo und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Surgery, University of Parma, Italy. Hauptthemen laut MEDLINE: Protein Glutamine gamma Glutamyltransferase 2, Breast Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: FAR2021.
Abstract (Originalsprache)
Transglutaminase 2 (TG2), which mediates post‐translational modifications of multiple intracellular enzymes, is involved in the pathogenesis and progression of cancer. We used 1 H‐NMR metabolomics to study the effects of AA9, a novel TG2 inhibitor, on two breast cancer cell lines with distinct phenotypes, MCF‐7 and MDA‐MB‐231. AA9 can promote apoptosis in both cell lines, but it is particularly effective in MD‐MB‐231, inhibiting transamidation reactions and decreasing cell migration and invasiveness. This metabolomics study provides evidence of a major effect of AA9 on MDA‐MB‐231 cells, impacting glutamate and aspartate metabolism, rather than on MCF‐7 cells, characterised by choline and O ‐phosphocholine decrease. Interestingly, AA9 treatment induces myo‐inositol alteration in both cell lines, indicating action on phosphatidylinositol metabolism, likely modulated by the G protein activity of TG2 on phospholipase C. Considering the metabolic deregulations that characterise various breast cancer subtypes, the existence of a metabolic pathway affected by AA9 further points to TG2 as a promising hot spot. The metabolomics approach provides a powerful tool to monitor the effectiveness of inhibitors and better understand the role of TG2 in cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine and Surgery, University of Parma, Italy.
- Department of Translational Medicine, University of Ferrara, Italy.
- Department of Animal Medicine, Production and Health (MAPS), University of Padua, Italy.
- Department of Neuroscience and Rehabilitation, University of Ferrara, Italy.
- Department of Environmental Sciences and Prevention, University of Ferrara, Italy.
- Department of Chemistry and Biomolecular Sciences, University of Ottawa, Canada.
ORCID-Profile: Mariana Gallo, Alberto Spisni, Nicoletta Bianchi
Förderung
- FAR2021
Zitieren
APA
Gallo, M., Ferrari, E., Terrazzan, A., Brugnoli, F., Spisni, A., Taccioli, C., Aguiari, G., Trentini, A., Volinia, S., Keillor, J. W., Bergamini, C. M., Bianchi, N., & Pertinhez, T. A. (2023). Metabolic characterisation of transglutaminase 2 inhibitor effects in breast cancer cell lines. The FEBS Journal. https://doi.org/10.1111/febs.16931
Vancouver
Gallo M, Ferrari E, Terrazzan A, Brugnoli F, Spisni A, Taccioli C, et al. Metabolic characterisation of transglutaminase 2 inhibitor effects in breast cancer cell lines. The FEBS Journal. 2023. doi:10.1111/febs.16931
BibTeX
@article{Gallo2023,
author = {Gallo, Mariana and Ferrari, Elena and Terrazzan, Anna and Brugnoli, Federica and Spisni, Alberto and Taccioli, Cristian and Aguiari, Gianluca and Trentini, Alessandro and Volinia, Stefano and Keillor, Jeffrey W and Bergamini, Carlo M and Bianchi, Nicoletta and Pertinhez, Thelma A},
title = {Metabolic characterisation of transglutaminase 2 inhibitor effects in breast cancer cell lines},
journal = {The FEBS Journal},
year = {2023},
doi = {10.1111/febs.16931}
}
EUVIMED